ACC Cell Subtyping and RAR/RXR Modulation for Ductal-Like Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adenoid cystic carcinomas (ACCs) are refractory to current treatments, including chemotherapy, immunotherapy, and targeted therapies, and their molecular causes, particularly the co-existence of myoepithelial-like and ductal-like cell populations, remain unclear, complicating differential sensitivity to anti-tumor therapies.
Innovation Solution
The use of single-cell RNA-sequencing (scRNA-seq) to identify cell-surface markers (CD49f, TP63, and KIT) for differential purification of myoepithelial-like and ductal-like cells, and manipulation of retinoic acid receptor (RAR) and retinoid-X receptor (RXR) signaling pathways to target these cell types, including the use of agonists (ATRA, bexarotene) and inhibitors (BMS493, AGN193109) to promote or suppress differentiation and selectively target ductal-like cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapies) are used for ACCs, then some treatment effect is achieved, but the treatments are unable to prevent metastatic relapse and patient death in approximately 60% of cases due to the co-existence of two populations of malignant cells with differential sensitivity to anti-tumor therapies
Solution Approach 1:
The patent segments the heterogeneous ACC cell population into two distinct subpopulations (ductal-like and myoepithelial-like cells) based on their differential sensitivity to anti-tumor therapies. This segmentation allows for targeted treatment strategies that address each cell population's specific therapeutic vulnerabilities, thereby improving overall treatment efficacy despite the heterogeneity of the tumor.
2Reliability
If surgery and radiotherapy are used for ACCs arising within the craniofacial district, then local control is achieved, but the treatments are destructive and unable to prevent metastatic relapse
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific destructive treatments (surgery, radiotherapy) to targeted molecular therapies that exploit the differential sensitivity of ACC cell populations. By identifying specific therapeutic vulnerabilities of each cell population, the treatment can achieve anti-tumor effects with reduced harmful side effects and better prevention of metastatic relapse.
3Loss of information
If the molecular causes of co-existence of myoepithelial-like and ductal-like cell populations are investigated, then understanding of tumor heterogeneity is improved, but the lack of experimental means to differentially isolate the two cell-types makes investigation difficult
Solution Approach 1:
The patent applies local quality by identifying and utilizing the distinct therapeutic sensitivities of each cell population as their distinguishing characteristic. This allows for differential isolation and study of myoepithelial-like and ductal-like cells through their differential responses to anti-tumor therapies, enabling molecular investigation without requiring physical separation methods.
Data Source
AI summary
This application is directed to methods and compositions related to the treatment and diagnosis of adenocarcinomas, such as adenoid cystic carcinoma (ACC). The methods and compositions related to the use of CD49f, TP63, and/or KIT/CD117 cell-surface markers for subtyping the cancer cells. One method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to inhibit the differentiation of myoepithelial-like cells into ductal-like cells. Another method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to selectively reduce the viability of ductal-like cells.